The University of Arizona

University of Texas System

Reglagene, Inc.

Arizona Board of Regents, a Body Corporate

Arizona Board of Regents on Behalf of the Unversit

Vijay Gokhale

Reena Chawla

Rajesh Khanna

May Khanna

Garth Powis

Daruka Mahadevan

Shuxing Zhang

Eugene A Mash

Emmanuelle J Meuillet

Teri C Suzuki

Laurence H Hurley

Louise Hecker

HyunJin Kang

Kui Wu

Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one novel compound disclosed herein to a subject having cancer. In some embodiments, methods of treating cancers can include administering a pharmaceutical composition disclosed herein to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one additional agent.

Compositions and methods for making and using small molecules in the treatment of cancer

The novel compounds, compositions and methods disclosed herein are effective for treating a subject having or suspected of developing a health condition, for example, cancer (i.e. brain cancer or a cancer metastasizing to the brain). The method of treating cancer can include administering a pharmaceutical composition to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one or more additional anti-cancer therapies. The compounds, compositions and methods can be further used for drug screening and other methods of detection and isolation.

Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

Small molecule antagonists of sumo related modification of CRMP2 and uses thereof

The present invention provides compounds that can modulate the amount of Nav1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav1.7 protein on the cellular surface and/or SUMOylation of CRMP2.

CRMP2 sumoylation inhibitors and uses thereof

The present invention relates to a compound of the formula: where n, Rand Rare those defined herein. The present invention also relates to use of a compound of Formula 1 in treating a clinical condition associated with fibrotic disorder. 

Indoline derivatives and method for using and producing the same

The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.

hTERT modulators and methods of use

The present invention provides compounds that can modulate the amount of Nav 1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav 1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav 1.7 protein on the cellular surface and/or SUMOylation of CRMP2.

CRMP2 SUMOylation inhibitors and uses thereof

Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Growing community of inventors

Tucson, AZ, United States of America

Vijay Gokhale